Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative...

8
Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012

Transcript of Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative...

Page 1: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Peter Hansen

Perspectives on Development Aid Health Impact Assessment

ASPHER/EAGHA Consultative WorkshopBrussels, 6 February 2012

Page 2: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

Principles that should underpin impact assessment

2

Central position of countries

What is the country’s impact?

To what extent do different factors, including development aid, contribute to that impact? How?

Impact is joint product of many causes, which operate through complex results chains

No cause is sufficient in itself to produce results

Contribution vs. attribution

Investments in impact assessment should recognize centrality of countries and explicitly focus on strengthening country ownership and capacities

Page 3: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

GAVI’s M&E Framework and Strategy

3

Page 4: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

Results framework

4

Page 5: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

Full country evaluations

5

Build upon country-owned M&E platform

Contribute to strengthening M&E of national health strategies and existing review mechanisms

Country teams participate in all phases as full partners

Harmonise and align evaluation investments and activities across agencies where appropriate

Prospective study design

Conduct over 5 years, concurrent with implementation

Entire results framework covered, from inputs to impact

Indicators and data sources defined in advance

Page 6: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

Full country evaluations

Baseline values documented from beginning, with data collection throughout

Focus on assessing country’s impact & identifying factors that meaningfully contribute to that impact; and how

Test assumptions in theory of change underpinning GAVI’s support to countries

Contextual factors that affect implementation—and positive and negative unintended consequences—explained and fully documented

Support ‘real time’ use of data and learning where possible at country and global levels

6

Page 7: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

How do the full country evaluations relate to model-based estimates of impact?

Models focus on measuring impact of vaccination at country level

Country results, not GAVI results

Evaluations test assumptions of modeling exercises through direct measurement of specific endpoints in 5 countries

Evaluations provide evidence to assess robustness of assumptions and adjust assumptions as appropriate

Evaluations identify how interplay of range of factors contributes to the observed result

7

Page 8: Peter Hansen Perspectives on Development Aid Health Impact Assessment ASPHER/EAGHA Consultative Workshop Brussels, 6 February 2012.

Consultative Workshop, ASPHER/EAGHABrussels, 6 February 2012

8